Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: Report from an Antimicrobial Surveillance Program (2013-2015).

Pfaller, MA ; Shortridge, D ; et al.

In: Journal of global antimicrobial resistance, Jg. 10 (2017-09-01), S. 186-194

academicJournal

Objectives: To evaluate the in vitro activity of ceftolozane-tazobactam and comparator agents tested against isolates of Enterobacteriaceae and Pseudomonas aeruginosa from patients in Australia and New Zealand with healthcare-associated infection.

Methods: A total of 1459 gram-negative organisms (440 P. aeruginosa and 1019 Enterobacteriaceae) were consecutively collected from 11 medical centers located in Australia and New Zealand. The organisms were tested for susceptibility by broth microdilution methods as described by the CLSI M07-A10 document and the results interpreted according to EUCAST and CLSI breakpoint criteria.

Results: Ceftolozane-tazobactam (MIC 50/90 , 0.25/0.5μg/mL; 97.7/95.9% susceptible [CLSI/EUCAST]), meropenem (MIC 50/90 , ≤0.06/≤0.06μg/mL; 99.8/99.9% susceptible [CLSI/EUCAST]) and amikacin (MIC 50/90 , 2/4μg/mL; 99.8/99.6% susceptible [CLSI/EUCAST]) were the most active compounds tested against Enterobacteriaceae. Enterobacteriaceae isolates displayed susceptibility rates to other β-lactam agents ranging from 95.3/94.4% for cefepime, 94.1/91.4% for piperacillin-tazobactam, and 93.3/91.5% for ceftazidime using CLSI/EUCAST breakpoints. Among the Enterobacteriaceae isolates tested, 0.1% were CRE and 6.6% exhibited an ESBL non-CRE phenotype. Whereas ceftolozane-tazobactam showed good activity against ESBL non-CRE phenotype strains of Enterobacteriaceae (MIC 50/90 , 0.5/2μg/mL), it lacked useful activity (MIC, >32μg/mL) against the single isolate with a CRE resistant phenotype. Ceftolozane-tazobactam was the most potent (MIC 50/90 , 0.5/2μg/mL) β-lactam agent tested against P. aeruginosa isolates, inhibiting 95.7% at an MIC of ≤4μg/mL.

Conclusions: Ceftolozane-tazobactam was the most active β-lactam agent tested against P. aeruginosa and demonstrated higher in vitro activity than currently available cephalosporins and piperacillin-tazobactam when tested against Enterobacteriaceae.

Titel:	Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: Report from an Antimicrobial Surveillance Program (2013-2015).
Autor/in / Beteiligte Person:	Pfaller, MA ; Shortridge, D ; Sader, HS ; Flamm, RK ; Castanheira, M
Zeitschrift:	Journal of global antimicrobial resistance, Jg. 10 (2017-09-01), S. 186-194
Veröffentlichung:	Amsterdam : Published by Elsevier Ltd. on behalf of International Society of Chemotherapy for Infection and Cancer, 2017
Medientyp:	academicJournal
ISSN:	2213-7173 (electronic)
DOI:	10.1016/j.jgar.2017.05.025
Schlagwort:	Anti-Bacterial Agents Australia Enterobacteriaceae isolation & purification Enterobacteriaceae Infections microbiology Humans Microbial Sensitivity Tests New Zealand Pseudomonas Infections microbiology Pseudomonas aeruginosa isolation & purification Cephalosporins pharmacology Cross Infection microbiology Drug Resistance, Multiple, Bacterial drug effects Enterobacteriaceae drug effects Pseudomonas aeruginosa drug effects Tazobactam pharmacology
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article; Research Support, Non-U.S. Gov't Language: English [J Glob Antimicrob Resist] 2017 Sep; Vol. 10, pp. 186-194. <i>Date of Electronic Publication: </i>2017 Jul 19. MeSH Terms: Cephalosporins / pharmacology ; Cross Infection / microbiology ; Drug Resistance, Multiple, Bacterial / drug effects ; Enterobacteriaceae / drug effects ; Pseudomonas aeruginosa / drug effects ; Tazobactam / pharmacology ; Anti-Bacterial Agents ; Australia ; Enterobacteriaceae / isolation & purification ; Enterobacteriaceae Infections / microbiology ; Humans ; Microbial Sensitivity Tests ; New Zealand ; Pseudomonas Infections / microbiology ; Pseudomonas aeruginosa / isolation & purification Contributed Indexing: Keywords: Australia; Ceftolozane–tazobactam; Drug resistance; Enterobacteriaceae; New Zealand; P. aeruginosa; Surveillance Substance Nomenclature: 0 (Anti-Bacterial Agents) ; 0 (Cephalosporins) ; 0 (ceftolozane, tazobactam drug combination) ; SE10G96M8W (Tazobactam) Entry Date(s): Date Created: 20170724 Date Completed: 20190513 Latest Revision: 20190513 Update Code: 20240513

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.